This prospective surveillance trial will gather safety information for Optison when it is
used in routine practice.
- The subject is over 18 years old.
- The subject has been scheduled for an Optison-enhanced echocardiography exam.
- The subject has provided signed and dated informed consent.
- Known hypersensitivity to perflutren, blood, blood products or albumin.